| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H11N3S |
| Molecular Weight | 217.29 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N=C1SC2=CC=CC=C2C3=NCCCN13
InChI
InChIKey=JNENSSREQFBZGT-UHFFFAOYSA-N
InChI=1S/C11H11N3S/c12-11-14-7-3-6-13-10(14)8-4-1-2-5-9(8)15-11/h1-2,4-5,12H,3,6-7H2
| Molecular Formula | C11H11N3S |
| Molecular Weight | 217.29 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
PD-404182 is an inhibitor of bacterial 2-keto-3-deoxyctulosonic acid (KDO) 8-P synthase. It is a virucidal compound that compromises the structural integrity of both hepatitis C virus and human immunodeficiency virus, likely by interacting with a nonlipid structural element of these viruses. In vitro studies revealed that PD-404182 physically disrupts variously pseudotyped lentiviruses and exposes the viral genomic RNA in a time- and temperature-dependent manner. Also, PD-404182 might be a tightly bound, covalent, or an irreversible inhibitor of human dimethylarginine dimethylaminohydrolase 1.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 9.0 µM [IC50] | |||
| 26.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
Anti-human immunodeficiency virus (HIV)-1 50% inhibitory concentration (IC50) of PD-404182, when diluted in seminal plasma, is ∼1 uM, is similar to the IC50 determined in cell culture growth medium, also PD-404182 retains full anti-HIV-1 activity after incubation in the cervical fluid at 37°C for at least 24 h. In addition, PD-404182 is nontoxic toward vaginal commensal Lactobacillus species (50% cytotoxic concentration [CC50] >300 uM), freshly activated human peripheral blood mononuclear cells (CC50 ∼200 uM), and primary CD4(+) T cells, macrophages, and dendritic cells (CC50 >300 μM).
